<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Biognosys</title>
	<atom:link href="https://biognosys.com/feed/" rel="self" type="application/rss+xml" />
	<link>https://biognosys.com/</link>
	<description>Next-Generation Proteomics</description>
	<lastBuildDate>Tue, 21 Apr 2026 14:32:16 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	

<image>
	<url>https://biognosys.com/content/uploads/2021/04/cropped-favicon-96x96-1-32x32.png</url>
	<title>Biognosys</title>
	<link>https://biognosys.com/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Affinity-Based Platforms and Unbiased Mass Spectrometry Combined for Enhanced Biomarker Discovery</title>
		<link>https://biognosys.com/affinity-based-platforms-and-unbiased-mass-spectrometry-combined-for-enhanced-biomarker-discovery/</link>
		
		<dc:creator><![CDATA[anna.jurkiewicz]]></dc:creator>
		<pubDate>Thu, 16 Apr 2026 11:19:13 +0000</pubDate>
				<category><![CDATA[Blog Posts]]></category>
		<category><![CDATA[Uncategorized]]></category>
		<guid isPermaLink="false">https://biognosys.com/?p=256304</guid>

					<description><![CDATA[<p><span data-contrast="auto">Plasma biomarker discovery sits at the heart of precision medicine, drug development, and translational research.</span></p>
<p>The post <a href="https://biognosys.com/affinity-based-platforms-and-unbiased-mass-spectrometry-combined-for-enhanced-biomarker-discovery/">Affinity-Based Platforms and Unbiased Mass Spectrometry Combined for Enhanced Biomarker Discovery</a> appeared first on <a href="https://biognosys.com">Biognosys</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The post <a href="https://biognosys.com/affinity-based-platforms-and-unbiased-mass-spectrometry-combined-for-enhanced-biomarker-discovery/">Affinity-Based Platforms and Unbiased Mass Spectrometry Combined for Enhanced Biomarker Discovery</a> appeared first on <a href="https://biognosys.com">Biognosys</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Beyond the Numbers: Why Targeted Proteomics Matters</title>
		<link>https://biognosys.com/beyond-the-numbers-why-targeted-proteomics-matters/</link>
		
		<dc:creator><![CDATA[anna.jurkiewicz]]></dc:creator>
		<pubDate>Thu, 02 Apr 2026 10:27:50 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<guid isPermaLink="false">https://biognosys.com/?p=251672</guid>

					<description><![CDATA[<p><span data-contrast="auto">Over the last decade, mass spectrometry–based proteomics has been on a clear mission: go deeper and go faster. </span></p>
<p>The post <a href="https://biognosys.com/beyond-the-numbers-why-targeted-proteomics-matters/">Beyond the Numbers: Why Targeted Proteomics Matters</a> appeared first on <a href="https://biognosys.com">Biognosys</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p><span class="TextRun SCXW58025304 BCX8" lang="EN-US" xml:lang="EN-US" data-contrast="auto"><span class="NormalTextRun SCXW58025304 BCX8">By </span><span class="NormalTextRun SCXW58025304 BCX8">Oliver R</span><span class="NormalTextRun SCXW58025304 BCX8">i</span><span class="NormalTextRun SCXW58025304 BCX8">nner, SVP </span><span class="NormalTextRun SCXW58025304 BCX8">of Biognosys</span><span class="NormalTextRun SCXW58025304 BCX8"> Group</span></span><span class="EOP SCXW58025304 BCX8" data-ccp-props="{&quot;335559738&quot;:240,&quot;335559739&quot;:240}"> </span></p>
<p>The post <a href="https://biognosys.com/beyond-the-numbers-why-targeted-proteomics-matters/">Beyond the Numbers: Why Targeted Proteomics Matters</a> appeared first on <a href="https://biognosys.com">Biognosys</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Immunopeptidomics Data Analysis: Challenges, Advances, and Applications</title>
		<link>https://biognosys.com/immunopeptidomics-data-analysis-challenges-advances-applications/</link>
		
		<dc:creator><![CDATA[anna.jurkiewicz]]></dc:creator>
		<pubDate>Tue, 20 Jan 2026 12:04:34 +0000</pubDate>
				<category><![CDATA[Blog Posts]]></category>
		<guid isPermaLink="false">https://biognosys.com/?p=225439</guid>

					<description><![CDATA[<p>As immunotherapies become increasingly sophisticated, researchers need reliable ways to understand how drugs influence antigen presentation and immune recognition.</p>
<p>The post <a href="https://biognosys.com/immunopeptidomics-data-analysis-challenges-advances-applications/">Immunopeptidomics Data Analysis: Challenges, Advances, and Applications</a> appeared first on <a href="https://biognosys.com">Biognosys</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The post <a href="https://biognosys.com/immunopeptidomics-data-analysis-challenges-advances-applications/">Immunopeptidomics Data Analysis: Challenges, Advances, and Applications</a> appeared first on <a href="https://biognosys.com">Biognosys</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Unlocking Biological Insight with Biognosys Software: A 2025 Publication Overview</title>
		<link>https://biognosys.com/unlocking-biological-insight-with-biognosys-software-a-2025-publication-overview/</link>
		
		<dc:creator><![CDATA[anna.jurkiewicz]]></dc:creator>
		<pubDate>Wed, 14 Jan 2026 12:14:42 +0000</pubDate>
				<category><![CDATA[Blog Posts]]></category>
		<guid isPermaLink="false">https://biognosys.com/?p=225063</guid>

					<description><![CDATA[<p>This blog explores how the Biognosys software ecosystem transforms complex proteomics data into confident biological discovery.</p>
<p>The post <a href="https://biognosys.com/unlocking-biological-insight-with-biognosys-software-a-2025-publication-overview/">Unlocking Biological Insight with Biognosys Software: A 2025 Publication Overview</a> appeared first on <a href="https://biognosys.com">Biognosys</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The post <a href="https://biognosys.com/unlocking-biological-insight-with-biognosys-software-a-2025-publication-overview/">Unlocking Biological Insight with Biognosys Software: A 2025 Publication Overview</a> appeared first on <a href="https://biognosys.com">Biognosys</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Pushing the Limits of Proteomics with Optimized Diagonal-PASEF and Spectronaut®</title>
		<link>https://biognosys.com/pushing-the-limits-of-proteomics-with-optimized-diagonal-pasef-and-spectronaut/</link>
		
		<dc:creator><![CDATA[anna.jurkiewicz]]></dc:creator>
		<pubDate>Mon, 15 Dec 2025 15:37:15 +0000</pubDate>
				<category><![CDATA[Blog Posts]]></category>
		<category><![CDATA[Uncategorized]]></category>
		<guid isPermaLink="false">https://biognosys.com/?p=223136</guid>

					<description><![CDATA[<p>Proteomics researchers are gaining a powerful new ally in their quest for deeper, faster, and more precise protein analysis. Recent collaborative work by Biognosys Group and Bruker demonstrates that the combination of diagonal-PASEF acquisition on the timsTOF HT platform with Spectronaut’s advanced data analysis capabilities is redefining what’s possible in discovery proteomics.</p>
<p>The post <a href="https://biognosys.com/pushing-the-limits-of-proteomics-with-optimized-diagonal-pasef-and-spectronaut/">Pushing the Limits of Proteomics with Optimized Diagonal-PASEF and Spectronaut&lt;sup&gt;®&lt;/sup&gt;</a> appeared first on <a href="https://biognosys.com">Biognosys</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The post <a href="https://biognosys.com/pushing-the-limits-of-proteomics-with-optimized-diagonal-pasef-and-spectronaut/">Pushing the Limits of Proteomics with Optimized Diagonal-PASEF and Spectronaut&lt;sup&gt;®&lt;/sup&gt;</a> appeared first on <a href="https://biognosys.com">Biognosys</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>How Can Library-Free directDIA Improve Immunopeptidomics with Spectronaut 20?</title>
		<link>https://biognosys.com/how-can-library-free-directdia-improve-immunopeptidomics-with-spectronaut-20/</link>
		
		<dc:creator><![CDATA[anna.jurkiewicz]]></dc:creator>
		<pubDate>Tue, 21 Oct 2025 13:12:34 +0000</pubDate>
				<category><![CDATA[Articles]]></category>
		<category><![CDATA[Blog Posts]]></category>
		<guid isPermaLink="false">https://biognosys.com/?p=216432</guid>

					<description><![CDATA[<p>For researchers in immunopeptidomics, the ability to capture a complete picture of the peptides presented by MHC molecules is central to understanding immune function and advancing therapeutic design. These peptides determine how the immune system distinguishes self from non-self and, as such, lie at the heart of many cutting-edge applications: vaccine development, cancer immunotherapy, autoimmune disease research, and more.</p>
<p>The post <a href="https://biognosys.com/how-can-library-free-directdia-improve-immunopeptidomics-with-spectronaut-20/">How Can Library-Free directDIA Improve Immunopeptidomics with Spectronaut 20?</a> appeared first on <a href="https://biognosys.com">Biognosys</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The post <a href="https://biognosys.com/how-can-library-free-directdia-improve-immunopeptidomics-with-spectronaut-20/">How Can Library-Free directDIA Improve Immunopeptidomics with Spectronaut 20?</a> appeared first on <a href="https://biognosys.com">Biognosys</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>From Evaluation to Implementation: Is the P2 Enrichment System the Right Fit for Your Lab?</title>
		<link>https://biognosys.com/is-the-p2-enrichment-system-the-right-fit-for-your-lab/</link>
		
		<dc:creator><![CDATA[anna.jurkiewicz]]></dc:creator>
		<pubDate>Wed, 14 May 2025 11:20:20 +0000</pubDate>
				<category><![CDATA[Blog Posts]]></category>
		<guid isPermaLink="false">https://biognosys.com/?p=135284</guid>

					<description><![CDATA[<p>The Challenge  &#160; Carina Sihlbom Wallem’s team at the Proteomics Core Facility, University of Gothenburg (Sweden)—a part of BioMS and SciLifeLab—was seeking a robust and user-friendly solution for comprehensive plasma profiling. Their objective was to implement a platform capable of efficiently and cost-effectively processing large-scale sample sets, while maintaining high standards of data quality and [&#8230;]</p>
<p>The post <a href="https://biognosys.com/is-the-p2-enrichment-system-the-right-fit-for-your-lab/">From Evaluation to Implementation: Is the P2 Enrichment System the Right Fit for Your Lab?</a> appeared first on <a href="https://biognosys.com">Biognosys</a>.</p>
]]></description>
										<content:encoded><![CDATA[<h4><span style="color: #be0a28;"><span class="TextRun SCXW77623668 BCX8" lang="EN-US" xml:lang="EN-US" data-contrast="auto"><span class="NormalTextRun SCXW77623668 BCX8"><span class="TextRun SCXW41491281 BCX8" lang="EN-US" xml:lang="EN-US" data-contrast="none"><span class="NormalTextRun SCXW41491281 BCX8">The </span><span class="NormalTextRun SCXW41491281 BCX8">Challenge</span></span><span class="EOP SCXW41491281 BCX8" data-ccp-props="{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335551550&quot;:1,&quot;335551620&quot;:1,&quot;335559685&quot;:0,&quot;335559737&quot;:0,&quot;335559738&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}"> </span></span></span></span></h4>
<p>&nbsp;</p>
<p><span class="TextRun SCXW20120109 BCX8" lang="EN-US" xml:lang="EN-US" data-contrast="auto"><span class="NormalTextRun SCXW20120109 BCX8"><span class="TextRun SCXW207682223 BCX8" lang="EN-US" xml:lang="EN-US" data-contrast="auto"><span class="NormalTextRun SCXW207682223 BCX8">Carina </span><span class="NormalTextRun SpellingErrorV2Themed SCXW207682223 BCX8">Sihlbom</span><span class="NormalTextRun SCXW207682223 BCX8"> Wallem’s team at the Proteomics Core Facility, University of Gothenburg (Sweden)—a part of </span><span class="NormalTextRun SpellingErrorV2Themed SCXW207682223 BCX8">BioMS</span><span class="NormalTextRun SCXW207682223 BCX8"> and </span><span class="NormalTextRun SpellingErrorV2Themed SCXW207682223 BCX8">SciLifeLab</span><span class="NormalTextRun SCXW207682223 BCX8">—was </span><span class="NormalTextRun SCXW207682223 BCX8">seeking</span><span class="NormalTextRun SCXW207682223 BCX8"> a robust and user-friendly solution for comprehensive plasma profiling. Their </span><span class="NormalTextRun SCXW207682223 BCX8">objective</span><span class="NormalTextRun SCXW207682223 BCX8"> was to implement a platform capable of efficiently and cost-effectively processing large-scale sample sets, while </span><span class="NormalTextRun SCXW207682223 BCX8">maintaining</span> <span class="NormalTextRun SCXW207682223 BCX8">high standards</span><span class="NormalTextRun SCXW207682223 BCX8"> of data quality and reproducibility.</span></span><span class="EOP SCXW207682223 BCX8" data-ccp-props="{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335551550&quot;:1,&quot;335551620&quot;:1,&quot;335559685&quot;:0,&quot;335559737&quot;:0,&quot;335559738&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}"> </span></span></span></p>
<h4><img decoding="async" class="alignnone size-medium wp-image-135290" src="https://biognosys.com/content/uploads/2025/05/Carina-Sihlbom-Wallem-quote-card-draft-4.png" alt="" width="1" height="1" /></h4>
<h4><span style="color: #be0a28;"><span class="TextRun SCXW77623668 BCX8" lang="EN-US" xml:lang="EN-US" data-contrast="auto"><span class="NormalTextRun SCXW77623668 BCX8"><span class="TextRun SCXW236090491 BCX8" lang="EN-US" xml:lang="EN-US" data-contrast="none"><span class="NormalTextRun SCXW236090491 BCX8">The Solution</span></span><span class="EOP SCXW236090491 BCX8" data-ccp-props="{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335551550&quot;:1,&quot;335551620&quot;:1,&quot;335559685&quot;:0,&quot;335559737&quot;:0,&quot;335559738&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}"> </span></span></span></span></h4>
<p>&nbsp;</p>
<p><span data-contrast="auto">Biognosys’ P2 Enrichment System is transforming plasma proteomics by enabling deep profiling of low-abundance proteins in human plasma and other biofluids. Powered by proprietary enrichment particles and optimized reagents, the system delivers exceptional plasma depth, reproducibility, and high-throughput performance—making it ideally suited for large-cohort studies.</span><span data-ccp-props="{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:1,&quot;335551620&quot;:1,&quot;335559738&quot;:240,&quot;335559739&quot;:240}"> </span></p>
<p><span data-ccp-props="{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335551550&quot;:1,&quot;335551620&quot;:1,&quot;335559738&quot;:240,&quot;335559739&quot;:240}"> </span></p>
<p>The team at the University of Gothenburg engaged in detailed discussions with Biognosys to explore the potential of implementing the P2 Enrichment System in their core facility. Following a comprehensive evaluation, they chose to proceed with the adoption of the platform. Below, Carina Sihlbom Wallem, Head of Unit at the Proteomics Core Facility, shares her firsthand experience with the implementation process.</p>
<p>&nbsp;</p>
<p><img fetchpriority="high" decoding="async" class="alignnone wp-image-135798 size-full" src="https://biognosys.com/content/uploads/2025/05/Carina-Sihlbom-Wallem-quote-card-final-small.png" alt="" width="2500" height="1309" srcset="https://biognosys.com/content/uploads/2025/05/Carina-Sihlbom-Wallem-quote-card-final-small.png 2500w, https://biognosys.com/content/uploads/2025/05/Carina-Sihlbom-Wallem-quote-card-final-small-300x157.png 300w, https://biognosys.com/content/uploads/2025/05/Carina-Sihlbom-Wallem-quote-card-final-small-1024x536.png 1024w, https://biognosys.com/content/uploads/2025/05/Carina-Sihlbom-Wallem-quote-card-final-small-768x402.png 768w, https://biognosys.com/content/uploads/2025/05/Carina-Sihlbom-Wallem-quote-card-final-small-1536x804.png 1536w, https://biognosys.com/content/uploads/2025/05/Carina-Sihlbom-Wallem-quote-card-final-small-2048x1072.png 2048w, https://biognosys.com/content/uploads/2025/05/Carina-Sihlbom-Wallem-quote-card-final-small-600x314.png 600w" sizes="(max-width: 2500px) 100vw, 2500px" /></p>
<h4></h4>
<p>&nbsp;</p>
<p>&nbsp;</p>
<h4><span style="color: #be0a28;"><span class="TextRun SCXW7738197 BCX8" lang="EN-US" xml:lang="EN-US" data-contrast="auto"><span class="NormalTextRun SCXW7738197 BCX8">User Perspective: Carina Sihlbom Wallem Reflects on Adopting the P2 Platform</span></span></span></h4>
<p>&nbsp;</p>
<p><strong>Can you tell us about your organization and the mission that drives your work? </strong></p>
<p><span class="TextRun SCXW20120109 BCX8" lang="EN-US" xml:lang="EN-US" data-contrast="auto"><span class="NormalTextRun SCXW20120109 BCX8">We are an open-access academic facility specializing in advanced mass spectrometry-based proteomics, including the analysis of post-translational modifications and protein quantification. It is incredibly rewarding to contribute to </span><span class="NormalTextRun SCXW20120109 BCX8">cutting-edge</span><span class="NormalTextRun SCXW20120109 BCX8"> research projects, and I am particularly passionate about </span><span class="NormalTextRun SCXW20120109 BCX8">leveraging</span><span class="NormalTextRun SCXW20120109 BCX8"> the latest technological advancements. This field thrives on continuous innovation.</span></span><span class="EOP SCXW20120109 BCX8" data-ccp-props="{}"> </span></p>
<p>&nbsp;</p>
<h4></h4>
<p><strong>What key benefits does P2 bring to your customers, and how does it enhance your existing plasma proteomics offering? </strong></p>
<p><span class="TextRun SCXW137101675 BCX8" lang="EN-US" xml:lang="EN-US" data-contrast="auto"><span class="NormalTextRun SCXW137101675 BCX8">Our goal is always to detect as many proteins as possible. Many disease-related biomarkers </span><span class="NormalTextRun SCXW137101675 BCX8">remain</span><span class="NormalTextRun SCXW137101675 BCX8"> elusive due to their low abundance, so increasing the number of quantifiable circulating proteins is crucial. The P2 platform enables comprehensive, unbiased protein discovery at a cost-effective rate for users.</span></span><span class="EOP SCXW137101675 BCX8" data-ccp-props="{}"> </span></p>
<h4><span style="color: #be0a28;"><span class="TextRun SCXW10263739 BCX8" lang="EN-US" xml:lang="EN-US" data-contrast="auto"><span class="NormalTextRun SCXW10263739 BCX8"> </span></span><span class="EOP SCXW10263739 BCX8" data-ccp-props="{}"> </span></span></h4>
<p><strong>Can you walk us through how you implemented P2 in your lab and what the role of the Biognosys implementation team was in this process?</strong></p>
<p><span class="TextRun SCXW90316846 BCX8" lang="EN-US" xml:lang="EN-US" data-contrast="auto"><span class="NormalTextRun SCXW90316846 BCX8">Before implementation, we held several productive virtual meetings to discuss </span><span class="NormalTextRun SCXW90316846 BCX8">the </span><span class="NormalTextRun SCXW90316846 BCX8">methodology</span><span class="NormalTextRun SCXW90316846 BCX8">, protocols, and required materials. Our samples were initially analyzed at Biognosys, followed by an on-site visit from the project manager. During this visit, the same samples were processed and analyzed in our facility under the guidance of the implementation team. The entire process was </span><span class="NormalTextRun SCXW90316846 BCX8">expertly coordinated, meeting our expectations and </span><span class="NormalTextRun SCXW90316846 BCX8">demonstrating</span><span class="NormalTextRun SCXW90316846 BCX8"> the team&#8217;s </span><span class="NormalTextRun SCXW90316846 BCX8">high level</span><span class="NormalTextRun SCXW90316846 BCX8"> of competence.</span></span><span class="EOP SCXW90316846 BCX8" data-ccp-props="{}"> </span></p>
<p>The post <a href="https://biognosys.com/is-the-p2-enrichment-system-the-right-fit-for-your-lab/">From Evaluation to Implementation: Is the P2 Enrichment System the Right Fit for Your Lab?</a> appeared first on <a href="https://biognosys.com">Biognosys</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Decoding Protein Modifications with Spectronaut: Normalizing Background Proteins for Accurate PTM Quantification</title>
		<link>https://biognosys.com/decoding-protein-modifications-with-spectronaut-normalizing-background-proteins-for-accurate-ptm-quantification/</link>
		
		<dc:creator><![CDATA[anna.jurkiewicz]]></dc:creator>
		<pubDate>Wed, 08 Jan 2025 09:04:00 +0000</pubDate>
				<category><![CDATA[Blog Posts]]></category>
		<guid isPermaLink="false">https://biognosys.com/?p=93244</guid>

					<description><![CDATA[<p>Understanding post-translational modifications (PTMs) is crucial in unraveling the complexities of protein function, particularly their role in health, disease, and therapeutic interventions. <strong>Spectronaut</strong><sup>®</sup> the gold standard DIA analysis software has introduced significant advancements in analyzing PTM stoichiometry and input normalization, offering new possibilities for proteomics researchers. In this blog article, we explore the transformative features of Spectronaut and their implications for proteomics research.</p>
<p>The post <a href="https://biognosys.com/decoding-protein-modifications-with-spectronaut-normalizing-background-proteins-for-accurate-ptm-quantification/">Decoding Protein Modifications with Spectronaut: Normalizing Background Proteins for Accurate PTM Quantification</a> appeared first on <a href="https://biognosys.com">Biognosys</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The post <a href="https://biognosys.com/decoding-protein-modifications-with-spectronaut-normalizing-background-proteins-for-accurate-ptm-quantification/">Decoding Protein Modifications with Spectronaut: Normalizing Background Proteins for Accurate PTM Quantification</a> appeared first on <a href="https://biognosys.com">Biognosys</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Why you should be using MS-based proteomics in hematology</title>
		<link>https://biognosys.com/why-you-should-be-using-ms-based-proteomics-in-hematology/</link>
		
		<dc:creator><![CDATA[Jakub Dyda]]></dc:creator>
		<pubDate>Wed, 03 Apr 2024 08:06:21 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<guid isPermaLink="false">https://biognosys.com/?p=61054</guid>

					<description><![CDATA[<p>Targeted protein degradation is an <a href="https://biognosys.com/why-is-targeted-protein-degradation-a-hot-topic-in-drug-development/" target="_blank" rel="noopener">innovative new therapeutic approach</a> that works by completely removing disease-associated proteins instead of inhibiting them. This approach can be used to develop more specific therapeutics with higher success rates that can target previously "undruggable" proteins.</p>
<p>The post <a href="https://biognosys.com/why-you-should-be-using-ms-based-proteomics-in-hematology/">Why you should be using MS-based proteomics in hematology</a> appeared first on <a href="https://biognosys.com">Biognosys</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The post <a href="https://biognosys.com/why-you-should-be-using-ms-based-proteomics-in-hematology/">Why you should be using MS-based proteomics in hematology</a> appeared first on <a href="https://biognosys.com">Biognosys</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Expanding horizons: Maximizing the potential of targeted protein degradation</title>
		<link>https://biognosys.com/maximizing-the-potential-of-targeted-protein-degradation/</link>
		
		<dc:creator><![CDATA[Anna Bjarkadottir]]></dc:creator>
		<pubDate>Tue, 13 Feb 2024 10:15:44 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<guid isPermaLink="false">https://biognosys.com/?p=56217</guid>

					<description><![CDATA[<p>Targeted protein degradation is an <a href="https://biognosys.com/why-is-targeted-protein-degradation-a-hot-topic-in-drug-development/" target="_blank" rel="noopener">innovative new therapeutic approach</a> that works by completely removing disease-associated proteins instead of inhibiting them. This approach can be used to develop more specific therapeutics with higher success rates that can target previously "undruggable" proteins.</p>
<p>The post <a href="https://biognosys.com/maximizing-the-potential-of-targeted-protein-degradation/">Expanding horizons: Maximizing the potential of targeted protein degradation</a> appeared first on <a href="https://biognosys.com">Biognosys</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The post <a href="https://biognosys.com/maximizing-the-potential-of-targeted-protein-degradation/">Expanding horizons: Maximizing the potential of targeted protein degradation</a> appeared first on <a href="https://biognosys.com">Biognosys</a>.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
